title: Efficacy and tolerance of everolimus in 123 consecutive advanced ER positive, HER2 negative breast cancer patients. A two center retrospective study.
abstract: BACKGROUND
  Since the publication of the Bolero-2 trial, everolimus has entered the routine care for advanced endocrine resistant luminal breast cancer (BC). We evaluated our practice 2 years after the French marketing authorization (July 2012).
  
  
  METHODS
  One hundred and twenty three consecutive patients were treated with everolimus combined with endocrine treatment in two French Cancer Centers. All patients had luminal (ER positive, HER2 negative) BC and had been previously treated with endocrine therapy for advanced disease.
  
  
  RESULTS
  Median age at initiation of everolimus was 63 y (36-84). Median delay from cancer diagnosis to everolimus was 12.6 y (1.3-34.8). Grade 2 or 3 side effects were experienced by 49.6% and 32.5% of the patients, respectively. Most frequent side effects were grade 2/3 mucositis (32.6%/11.2%), grade 1/2 decreased appetite (24.4%/13.8%), and grade 1/2 rash (28.5%/13.8%). At a median follow up of 10 months, median progression free survival was 9 months (0.4-26+), and median overall survival was 21 months (0.4-26+).
  
  
  CONCLUSIONS
  In routine practice everolimus efficacy appears very close to the Bolero-2 results, although in more heavily pretreated patients. Everolimus based therapy appears feasible and side effects are similar to those previously reported. These data support the use of everolimus in daily practice.
authors.affiliation: Departments of Medical Oncology, Institut Curie, 26 rue d'Ulm, 75005 Paris, France.
authors.forename: D
authors.initials: D
authors.lastname: Chocteau-Bouju
authors.affiliation: Departments of Medical Oncology, Institut Bergonié, 229 Cours de l'Argonne, 33000 Bordeaux, France.
authors.forename: C
authors.initials: C
authors.lastname: Chakiba
authors.affiliation: Departments of Medical Oncology, Institut Curie, 26 rue d'Ulm, 75005 Paris, France.
authors.forename: L
authors.initials: L
authors.lastname: Mignot
authors.affiliation: Departments of Medical Oncology, Institut Bergonié, 229 Cours de l'Argonne, 33000 Bordeaux, France.
authors.forename: N
authors.initials: N
authors.lastname: Madranges
authors.affiliation: Departments of Medical Oncology, Institut Curie, 26 rue d'Ulm, 75005 Paris, France.
authors.forename: J-Y
authors.initials: JY
authors.lastname: Pierga
authors.affiliation: Departments of Medical Oncology, Institut Curie, 26 rue d'Ulm, 75005 Paris, France.
authors.forename: P
authors.initials: P
authors.lastname: Beuzeboc
authors.affiliation: Departments of Medical Oncology, Institut Bergonié, 229 Cours de l'Argonne, 33000 Bordeaux, France.
authors.forename: N
authors.initials: N
authors.lastname: Quenel-Tueux
authors.affiliation: Departments of Medical Oncology, Institut Curie, 26 rue d'Ulm, 75005 Paris, France.
authors.forename: V
authors.initials: V
authors.lastname: Dieras
authors.affiliation: Departments of Medical Oncology, Institut Bergonié, 229 Cours de l'Argonne, 33000 Bordeaux, France.
authors.forename: H
authors.initials: H
authors.lastname: Bonnefoi
authors.affiliation: Departments of Medical Oncology, Institut Bergonié, 229 Cours de l'Argonne, 33000 Bordeaux, France.
authors.forename: M
authors.initials: M
authors.lastname: Debled
authors.affiliation: Departments of Medical Oncology, Institut Curie, 26 rue d'Ulm, 75005 Paris, France. Electronic address: paul.cottu@curie.fr.
authors.forename: P
authors.initials: P
authors.lastname: Cottu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001066:Appetite / Q000187:drug effects; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000473:pathology; D000068338:Everolimus / Q000627:therapeutic use*; D005076:Exanthema / Q000139:chemically induced; D005260:Female; D005602:France; D006801:Humans; D008875:Middle Aged; D052016:Mucositis / Q000139:chemically induced; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D011960:Receptors, Estrogen / Q000032:analysis; D012189:Retrospective Studies; D061665:Time-to-Treatment; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D000068338:Everolimus; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; C508053:ERBB2 protein, human
keywords: Advanced breast cancer; Clinical practice; Everolimus